Patents by Inventor Nina Heiss

Nina Heiss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR THE TREATMENT OF TUMORS WITH INDANE COMPOUNDS
    Publication number: 20120130147
    Abstract: Compounds of the formula (I), in which R1, R2, R3, R4, and q have the meanings indicated in Claim 1, can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: January 25, 2012
    Publication date: May 24, 2012
    Inventors: Dirk FINSINGER, David Bruge, Hans-Peter Buchstaller, Ulrich Emde, Kai Schiemann, Wolfgang Staehle, Christiane Amendt, Nina Heiss, Frank Zenke
  • Substituted tetrahydroquinolines
    Patent number: 7893082
    Abstract: Disclosed are compounds of formula (I), wherein W, R, R1, R2, R3, R4, R5, R6, and R7 have the meanings indicated in claim 1. Said compounds can be used for the treatment of tumors, among other things.
    Type: Grant
    Filed: May 17, 2006
    Date of Patent: February 22, 2011
    Assignee: Merck Patent GmbH
    Inventors: Kai Schiemann, Ulrich Emde, Dirk Finsinger, Christiane Amendt, Nina Heiss, Frank Zenke
  • INDANES
    Publication number: 20090118267
    Abstract: Compounds of the formula (I), in which R1, R2, R3, R4, and q have the meanings indicated in claim 1, can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: February 13, 2006
    Publication date: May 7, 2009
    Inventors: Dirk Finsinger, David Bruge, Hans-Peter Buchstaller, Ulrich Emde, Kai Schiemann, Wolfgang Staehle, Christiane Amendt, Nina Heiss, Frank Zenke
  • Substituted Tetrahydroquinolines
    Publication number: 20080194615
    Abstract: Disclosed are compounds of formula (I), wherein W, R, R1, R2, R3, R4, R5, R6, and R7 have the meanings indicated in claim 1. Said compounds can be used for the treatment of tumors, among other things.
    Type: Application
    Filed: May 17, 2006
    Publication date: August 14, 2008
    Applicant: Merck Patent GmbH
    Inventors: Kai Schiemann, Ulrich Emde, Dirk Finsinger, Christiane Amendt, Nina Heiss, Frank Zenke
  • Dihydrobenzothiophenes
    Publication number: 20070219246
    Abstract: Compounds of the formula (I) in which W, R1, R2, R3, R4, and q have the meanings indicated in Claim 1, can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: April 28, 2005
    Publication date: September 20, 2007
    Inventors: Dirk Finsinger, Soheila Anzali, Matthias Frech, Johannes Gleitz, Nina Heiss, Bjoern Hock, Kai Schiemann, Frank Zenke
  • Diagnosis and treatment of medical conditions associated with defective NFkappa B(NF-&kgr;B) activation
    Patent number: 6824972
    Abstract: Incontinentia Pigmenti (IP) is a neurocutaneous genodermatosis that segregates as an X-linked dominant disorder with a high probability of prenatal male lethality. A locus in Xq28 containing NF-&kgr;B Essential Modulator, a gene product involved in the activation of NF-kB and central to many pro-inflammatory and apoptotic pathways, contains mutations in the majority of cases of IP. Disclosed are methods, compositions and kits directed to a defect in a NF-&kgr;B related disease such as IP.
    Type: Grant
    Filed: May 22, 2001
    Date of Patent: November 30, 2004
    Assignees: Baylor College of Medicine, Cambridge University Technical Services Limited, Consiglio Nazionale Delle Richerche, INSERM, L'Institut Pasteur
    Inventors: Sue J. Kenwrick, Hayley Woffendin, Arnold Munnich, Asmae Smahi, Alain Israel, Annemarie Poustka, Nina Heiss, Michele D'Urso, Richard A. Lewis, David L. Nelson, Swaroop Aradhya, Moise Levy
  • Diagnosis and treatment of medical conditions associated with defective NFkappa B(NF-kappaB) activation
    Publication number: 20030032055
    Abstract: Incontinentia Pigmenti (IP) is a neurocutaneous genodermatosis that segregates as an X-linked dominant disorder with a high probability of prenatal male lethality. A locus in Xq28 containing NF-&kgr;B Essential Modulator, a gene product involved in the activation of NF-kB and central to many pro-inflammatory and apoptotic pathways, contains mutations in the majority of cases of IP. Disclosed are methods, compositions and kits directed to a defect in a NF-&kgr;B related disease such as IP.
    Type: Application
    Filed: May 22, 2001
    Publication date: February 13, 2003
    Inventors: Sue J. Kenwrick, Hayley Woffendin, Arnold Munnich, Asmae Smahi, Alain Israel, Annemarie Poustka, Nina Heiss, Michele D'Urso, Richard Alan Lewis, David L. Nelson, Swaroop Aradhya, Moise Levy